Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Leukemia & Lymphoma Specialty Channel

Quiz
Combination of Pembrolizumab and Vorinostat for PD-1 Blockade Refractory cHL
03/25/2024
What was the key finding from a dose-expansion study assessing a combination of pembrolizumab plus vorinostat among patients with R/R classical Hodgkin lymphoma, particularly among those refractory to PD-1 blockade?
What was the key finding from a dose-expansion study assessing a combination of pembrolizumab plus vorinostat among patients with R/R classical Hodgkin lymphoma, particularly among those refractory to PD-1 blockade?
What was the key finding from a...
03/25/2024
Oncology
News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024

Jordan Kadish

Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology
News
Romidepsin Plus CHOP vs CHOP Alone for Previously Untreated Peripheral T-Cell Lymphoma
03/15/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide, doxorubicin, vincristine, and prednisone with romidepsin did not yield improved efficacy for patients with previously untreated peripheral T-cell lymphoma compared to CHOP alone, according to the phase 3 Ro-CHOP trial.
Cyclophosphamide, doxorubicin, vincristine, and prednisone with romidepsin did not yield improved efficacy for patients with previously untreated peripheral T-cell lymphoma compared to CHOP alone, according to the phase 3 Ro-CHOP trial.
Cyclophosphamide, doxorubicin,...
03/15/2024
Oncology
News
All-Trans Retinoic Acid and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin and Idarubicin Highly Effective for Treating Relapsed Acute Promyelocytic Leukemia
03/06/2024

Amber Denham

Amber Denham
The combination of all-trans retinoic acid and arsenic trioxide with or without gemtuzumab ozogamicin and idarubicin is a highly effective salvage therapy for patients with relapsed acute promyelocytic leukemia, according to a recent study.
The combination of all-trans retinoic acid and arsenic trioxide with or without gemtuzumab ozogamicin and idarubicin is a highly effective salvage therapy for patients with relapsed acute promyelocytic leukemia, according to a recent study.
The combination of all-trans...
03/06/2024
Oncology
News
Doxorubicin, Vinblastine, and Dacarbazine Effective for Advanced Stage Hodgkin Lymphoma, Including With Brentuximab Vedotin Dose Reduction
03/06/2024

Amber Denham

Amber Denham
According to a real-world analysis, doxorubicin, vinblastine, and dacarbazine demonstrates a highly efficacy for patients with advanced stage classic Hodgkin lymphoma, including those with prominent dose reductions or omission of brentuximab...
According to a real-world analysis, doxorubicin, vinblastine, and dacarbazine demonstrates a highly efficacy for patients with advanced stage classic Hodgkin lymphoma, including those with prominent dose reductions or omission of brentuximab...
According to a real-world...
03/06/2024
Oncology
Quiz
Excluding INRT Among ePet-Negative Patients With Localized Hodgkin Lymphoma
02/23/2024
According to an analysis of a 10-year follow-up of the EORTC/LYSA/FIL H10 trial, the exclusion of involved-node radiotherapy was correlated with ____ progression-free survival among ePET-negative patients with localized Hodgkin lymphoma. The...
According to an analysis of a 10-year follow-up of the EORTC/LYSA/FIL H10 trial, the exclusion of involved-node radiotherapy was correlated with ____ progression-free survival among ePET-negative patients with localized Hodgkin lymphoma. The...
According to an analysis of a...
02/23/2024
Oncology
Quiz
Treating HIV-cHL With Brentuximab Vedotin-AVD
02/20/2024
According to a phase 1/2 study, what treatment regimen yielded encouraging efficacy and tolerability among patients with untreated stage 2 to 4 HIV-associated classical Hodgkin lymphoma?
According to a phase 1/2 study, what treatment regimen yielded encouraging efficacy and tolerability among patients with untreated stage 2 to 4 HIV-associated classical Hodgkin lymphoma?
According to a phase 1/2 study,...
02/20/2024
Oncology
News
Golidocitinib Yields Favorable Benefit-Risk Profile Among Heavily Pretreated Patients With R/R PTCL
01/31/2024

Jordan Kadish

Jordan Kadish
Golidocitinib, a JAK1 inhibitor, yielded a favorable benefit-risk profile among heavily pre-treated patients with R/R peripheral T-cell lymphoma, according to the phase 2 JACKPOT8 trial.
Golidocitinib, a JAK1 inhibitor, yielded a favorable benefit-risk profile among heavily pre-treated patients with R/R peripheral T-cell lymphoma, according to the phase 2 JACKPOT8 trial.
Golidocitinib, a JAK1 inhibitor,...
01/31/2024
Oncology
News
ASCT Demonstrates Efficacy as Salvage Approach for Patients With Classical Hodgkin Lymphoma Treated With PET-Adapted Therapies
01/24/2024

Amber Denham

Amber Denham
According to a retrospective study, autologous stem cell transplantation and high-dose chemotherapy showed efficacy as a salvage approach for patients with classical Hodgkin lymphoma with positron-emission-tomography-adapted therapies.
According to a retrospective study, autologous stem cell transplantation and high-dose chemotherapy showed efficacy as a salvage approach for patients with classical Hodgkin lymphoma with positron-emission-tomography-adapted therapies.
According to a retrospective...
01/24/2024
Oncology
News
Pembrolizumab Plus Vorinostat Shows Tolerable Safety and Promising Responses for Patients With PD-1 Blockade Refractory Classical Hodgkin Lymphoma
01/17/2024

Jordan Kadish

Jordan Kadish
A combination of pembrolizumab plus vorinostat exhibited tolerable safety and promising overall response rates among patients with classical Hodgkin lymphoma refractory to PD-1 blockade, according to a phase 1 dose expansion study.
A combination of pembrolizumab plus vorinostat exhibited tolerable safety and promising overall response rates among patients with classical Hodgkin lymphoma refractory to PD-1 blockade, according to a phase 1 dose expansion study.
A combination of pembrolizumab...
01/17/2024
Oncology
News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024

Jordan Kadish

Jordan Kadish
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology

News

News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024

Jordan Kadish

Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology
News
Romidepsin Plus CHOP vs CHOP Alone for Previously Untreated Peripheral T-Cell Lymphoma
03/15/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide, doxorubicin, vincristine, and prednisone with romidepsin did not yield improved efficacy for patients with previously untreated peripheral T-cell lymphoma compared to CHOP alone, according to the phase 3 Ro-CHOP trial.
Cyclophosphamide, doxorubicin, vincristine, and prednisone with romidepsin did not yield improved efficacy for patients with previously untreated peripheral T-cell lymphoma compared to CHOP alone, according to the phase 3 Ro-CHOP trial.
Cyclophosphamide, doxorubicin,...
03/15/2024
Oncology
News
All-Trans Retinoic Acid and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin and Idarubicin Highly Effective for Treating Relapsed Acute Promyelocytic Leukemia
03/06/2024

Amber Denham

Amber Denham
The combination of all-trans retinoic acid and arsenic trioxide with or without gemtuzumab ozogamicin and idarubicin is a highly effective salvage therapy for patients with relapsed acute promyelocytic leukemia, according to a recent study.
The combination of all-trans retinoic acid and arsenic trioxide with or without gemtuzumab ozogamicin and idarubicin is a highly effective salvage therapy for patients with relapsed acute promyelocytic leukemia, according to a recent study.
The combination of all-trans...
03/06/2024
Oncology
News
Doxorubicin, Vinblastine, and Dacarbazine Effective for Advanced Stage Hodgkin Lymphoma, Including With Brentuximab Vedotin Dose Reduction
03/06/2024

Amber Denham

Amber Denham
According to a real-world analysis, doxorubicin, vinblastine, and dacarbazine demonstrates a highly efficacy for patients with advanced stage classic Hodgkin lymphoma, including those with prominent dose reductions or omission of brentuximab...
According to a real-world analysis, doxorubicin, vinblastine, and dacarbazine demonstrates a highly efficacy for patients with advanced stage classic Hodgkin lymphoma, including those with prominent dose reductions or omission of brentuximab...
According to a real-world...
03/06/2024
Oncology
News
Golidocitinib Yields Favorable Benefit-Risk Profile Among Heavily Pretreated Patients With R/R PTCL
01/31/2024

Jordan Kadish

Jordan Kadish
Golidocitinib, a JAK1 inhibitor, yielded a favorable benefit-risk profile among heavily pre-treated patients with R/R peripheral T-cell lymphoma, according to the phase 2 JACKPOT8 trial.
Golidocitinib, a JAK1 inhibitor, yielded a favorable benefit-risk profile among heavily pre-treated patients with R/R peripheral T-cell lymphoma, according to the phase 2 JACKPOT8 trial.
Golidocitinib, a JAK1 inhibitor,...
01/31/2024
Oncology
News
ASCT Demonstrates Efficacy as Salvage Approach for Patients With Classical Hodgkin Lymphoma Treated With PET-Adapted Therapies
01/24/2024

Amber Denham

Amber Denham
According to a retrospective study, autologous stem cell transplantation and high-dose chemotherapy showed efficacy as a salvage approach for patients with classical Hodgkin lymphoma with positron-emission-tomography-adapted therapies.
According to a retrospective study, autologous stem cell transplantation and high-dose chemotherapy showed efficacy as a salvage approach for patients with classical Hodgkin lymphoma with positron-emission-tomography-adapted therapies.
According to a retrospective...
01/24/2024
Oncology
News
Pembrolizumab Plus Vorinostat Shows Tolerable Safety and Promising Responses for Patients With PD-1 Blockade Refractory Classical Hodgkin Lymphoma
01/17/2024

Jordan Kadish

Jordan Kadish
A combination of pembrolizumab plus vorinostat exhibited tolerable safety and promising overall response rates among patients with classical Hodgkin lymphoma refractory to PD-1 blockade, according to a phase 1 dose expansion study.
A combination of pembrolizumab plus vorinostat exhibited tolerable safety and promising overall response rates among patients with classical Hodgkin lymphoma refractory to PD-1 blockade, according to a phase 1 dose expansion study.
A combination of pembrolizumab...
01/17/2024
Oncology
News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024

Jordan Kadish

Jordan Kadish
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
News
Golidocitinib Yields Acceptable Safety, Promising Efficacy Among Patients With Heavily Pretreated R/R Peripheral T-Cell Lymphomas
01/08/2024

Jordan Kadish

Jordan Kadish
JAK1 selective inhibitor golidocitinib demonstrated tolerable safety and encouraging antitumor efficacy among patients with heavily pretreated R/R peripheral T-cell lymphomas.
JAK1 selective inhibitor golidocitinib demonstrated tolerable safety and encouraging antitumor efficacy among patients with heavily pretreated R/R peripheral T-cell lymphomas.
JAK1 selective inhibitor...
01/08/2024
Oncology
News
FDA Raises Concern About Serious Risk of Secondary T-Cell Malignancy Among Patients Treated With CAR T-Cell Therapies
12/05/2023

Jordan Kadish

Jordan Kadish
On November 28, 2023, the FDA reported on the serious risks of secondary T-cell malignancies developing among patients treated with approved BCMA- or CD19 genetically modified autologous CAR T-cell immunotherapies.
On November 28, 2023, the FDA reported on the serious risks of secondary T-cell malignancies developing among patients treated with approved BCMA- or CD19 genetically modified autologous CAR T-cell immunotherapies.
On November 28, 2023, the FDA...
12/05/2023
Oncology

Interactive Features

Quiz
Combination of Pembrolizumab and Vorinostat for PD-1 Blockade Refractory cHL
03/25/2024
What was the key finding from a dose-expansion study assessing a combination of pembrolizumab plus vorinostat among patients with R/R classical Hodgkin lymphoma, particularly among those refractory to PD-1 blockade?
What was the key finding from a dose-expansion study assessing a combination of pembrolizumab plus vorinostat among patients with R/R classical Hodgkin lymphoma, particularly among those refractory to PD-1 blockade?
What was the key finding from a...
03/25/2024
Oncology
Quiz
Excluding INRT Among ePet-Negative Patients With Localized Hodgkin Lymphoma
02/23/2024
According to an analysis of a 10-year follow-up of the EORTC/LYSA/FIL H10 trial, the exclusion of involved-node radiotherapy was correlated with ____ progression-free survival among ePET-negative patients with localized Hodgkin lymphoma. The...
According to an analysis of a 10-year follow-up of the EORTC/LYSA/FIL H10 trial, the exclusion of involved-node radiotherapy was correlated with ____ progression-free survival among ePET-negative patients with localized Hodgkin lymphoma. The...
According to an analysis of a...
02/23/2024
Oncology
Quiz
Treating HIV-cHL With Brentuximab Vedotin-AVD
02/20/2024
According to a phase 1/2 study, what treatment regimen yielded encouraging efficacy and tolerability among patients with untreated stage 2 to 4 HIV-associated classical Hodgkin lymphoma?
According to a phase 1/2 study, what treatment regimen yielded encouraging efficacy and tolerability among patients with untreated stage 2 to 4 HIV-associated classical Hodgkin lymphoma?
According to a phase 1/2 study,...
02/20/2024
Oncology
Quiz
Radiomics Features and Prediction of Outcomes for Aggressive B-Cell Lymphoma
06/09/2023
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study...
06/09/2023
Oncology
Quiz
Pembrolizumab Plus ICE Chemotherapy for Classic Hodgkin Lymphoma
05/23/2023
True or False: In a study assessing the efficacy and safety of the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide (ICE) chemotherapy for the treatment of classic Hodgkin lymphoma, the complete response rate among the...
True or False: In a study assessing the efficacy and safety of the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide (ICE) chemotherapy for the treatment of classic Hodgkin lymphoma, the complete response rate among the...
True or False: In a study...
05/23/2023
Oncology
Quiz
A-HIPI for Prediction of Clinical Outcomes of Classic Hodgkin Lymphoma
05/10/2023
True or False: The Advanced-Stage Hodgkin Lymphoma International Prognostic Index, or A-HIPI, improved calibration for progression-free survival and overall survival compared to previous prognostic tools used to predict clinical outcomes of...
True or False: The Advanced-Stage Hodgkin Lymphoma International Prognostic Index, or A-HIPI, improved calibration for progression-free survival and overall survival compared to previous prognostic tools used to predict clinical outcomes of...
True or False: The...
05/10/2023
Oncology
Quiz
Toleration of Sugemalimab Monotherapy Among Patients With R/R Extranodal Natural Killer/T-Cell Lymphoma
04/27/2023
True or False: Sugemalimab treatment was poorly tolerated among patients with relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (ENKTL), according to a phase 2 study.
True or False: Sugemalimab treatment was poorly tolerated among patients with relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (ENKTL), according to a phase 2 study.
True or False: Sugemalimab...
04/27/2023
Oncology
Quiz
Quiz: Iberdomide Plus Anti-CD20 Monoclonal Antibody for R/R Lymphoma
03/31/2023
True or False: In a study assessing the efficacy and safety of iberdomide (CC-220) plus an anti-CD20 monoclonal antibody for treating R/R lymphoma, iberdomide was rapidly absorbed and exposure increased in a dose-related manner.
True or False: In a study assessing the efficacy and safety of iberdomide (CC-220) plus an anti-CD20 monoclonal antibody for treating R/R lymphoma, iberdomide was rapidly absorbed and exposure increased in a dose-related manner.
True or False: In a study...
03/31/2023
Oncology
Quiz
Quiz: Impact of CD19 CAR T-Cell Product Type on Aggressive B-Cell Non-Hodgkin Lymphoma
09/02/2022
True or False: Study findings suggest that CD19 CAR T-cell product type independently impacts toxicity and efficacy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
True or False: Study findings suggest that CD19 CAR T-cell product type independently impacts toxicity and efficacy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
True or False: Study findings...
09/02/2022
Oncology
phone
Test Your Knowledge
Quiz: Does This Combo Therapy Show Safety in DLBCL?
12/17/2021
True or false: A phase 2 study of naratuximab emtansine found it has limited safety and efficacy for patients with DLBCL and other B-cell NHLs.
True or false: A phase 2 study of naratuximab emtansine found it has limited safety and efficacy for patients with DLBCL and other B-cell NHLs.
True or false: A phase 2 study...
12/17/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Safety Outcomes of Bendamustine Treatment Among Patients With Indolent Non-Hodgkin Lymphoma in Real-World Setting
03/22/2024

Jordan Kadish

Jordan Kadish
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial and analysis, the safety outcomes of bendamustine treatment among patients with indolent non-Hodgkin lymphoma in routine practice were comparable to trial population outcomes.
According to a real-world trial...
03/22/2024
Oncology
News
Romidepsin Plus CHOP vs CHOP Alone for Previously Untreated Peripheral T-Cell Lymphoma
03/15/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide, doxorubicin, vincristine, and prednisone with romidepsin did not yield improved efficacy for patients with previously untreated peripheral T-cell lymphoma compared to CHOP alone, according to the phase 3 Ro-CHOP trial.
Cyclophosphamide, doxorubicin, vincristine, and prednisone with romidepsin did not yield improved efficacy for patients with previously untreated peripheral T-cell lymphoma compared to CHOP alone, according to the phase 3 Ro-CHOP trial.
Cyclophosphamide, doxorubicin,...
03/15/2024
Oncology
News
All-Trans Retinoic Acid and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin and Idarubicin Highly Effective for Treating Relapsed Acute Promyelocytic Leukemia
03/06/2024

Amber Denham

Amber Denham
The combination of all-trans retinoic acid and arsenic trioxide with or without gemtuzumab ozogamicin and idarubicin is a highly effective salvage therapy for patients with relapsed acute promyelocytic leukemia, according to a recent study.
The combination of all-trans retinoic acid and arsenic trioxide with or without gemtuzumab ozogamicin and idarubicin is a highly effective salvage therapy for patients with relapsed acute promyelocytic leukemia, according to a recent study.
The combination of all-trans...
03/06/2024
Oncology
News
Doxorubicin, Vinblastine, and Dacarbazine Effective for Advanced Stage Hodgkin Lymphoma, Including With Brentuximab Vedotin Dose Reduction
03/06/2024

Amber Denham

Amber Denham
According to a real-world analysis, doxorubicin, vinblastine, and dacarbazine demonstrates a highly efficacy for patients with advanced stage classic Hodgkin lymphoma, including those with prominent dose reductions or omission of brentuximab...
According to a real-world analysis, doxorubicin, vinblastine, and dacarbazine demonstrates a highly efficacy for patients with advanced stage classic Hodgkin lymphoma, including those with prominent dose reductions or omission of brentuximab...
According to a real-world...
03/06/2024
Oncology
News
Golidocitinib Yields Favorable Benefit-Risk Profile Among Heavily Pretreated Patients With R/R PTCL
01/31/2024

Jordan Kadish

Jordan Kadish
Golidocitinib, a JAK1 inhibitor, yielded a favorable benefit-risk profile among heavily pre-treated patients with R/R peripheral T-cell lymphoma, according to the phase 2 JACKPOT8 trial.
Golidocitinib, a JAK1 inhibitor, yielded a favorable benefit-risk profile among heavily pre-treated patients with R/R peripheral T-cell lymphoma, according to the phase 2 JACKPOT8 trial.
Golidocitinib, a JAK1 inhibitor,...
01/31/2024
Oncology
News
ASCT Demonstrates Efficacy as Salvage Approach for Patients With Classical Hodgkin Lymphoma Treated With PET-Adapted Therapies
01/24/2024

Amber Denham

Amber Denham
According to a retrospective study, autologous stem cell transplantation and high-dose chemotherapy showed efficacy as a salvage approach for patients with classical Hodgkin lymphoma with positron-emission-tomography-adapted therapies.
According to a retrospective study, autologous stem cell transplantation and high-dose chemotherapy showed efficacy as a salvage approach for patients with classical Hodgkin lymphoma with positron-emission-tomography-adapted therapies.
According to a retrospective...
01/24/2024
Oncology
News
Pembrolizumab Plus Vorinostat Shows Tolerable Safety and Promising Responses for Patients With PD-1 Blockade Refractory Classical Hodgkin Lymphoma
01/17/2024

Jordan Kadish

Jordan Kadish
A combination of pembrolizumab plus vorinostat exhibited tolerable safety and promising overall response rates among patients with classical Hodgkin lymphoma refractory to PD-1 blockade, according to a phase 1 dose expansion study.
A combination of pembrolizumab plus vorinostat exhibited tolerable safety and promising overall response rates among patients with classical Hodgkin lymphoma refractory to PD-1 blockade, according to a phase 1 dose expansion study.
A combination of pembrolizumab...
01/17/2024
Oncology
News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024

Jordan Kadish

Jordan Kadish
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
News
Golidocitinib Yields Acceptable Safety, Promising Efficacy Among Patients With Heavily Pretreated R/R Peripheral T-Cell Lymphomas
01/08/2024

Jordan Kadish

Jordan Kadish
JAK1 selective inhibitor golidocitinib demonstrated tolerable safety and encouraging antitumor efficacy among patients with heavily pretreated R/R peripheral T-cell lymphomas.
JAK1 selective inhibitor golidocitinib demonstrated tolerable safety and encouraging antitumor efficacy among patients with heavily pretreated R/R peripheral T-cell lymphomas.
JAK1 selective inhibitor...
01/08/2024
Oncology
News
FDA Raises Concern About Serious Risk of Secondary T-Cell Malignancy Among Patients Treated With CAR T-Cell Therapies
12/05/2023

Jordan Kadish

Jordan Kadish
On November 28, 2023, the FDA reported on the serious risks of secondary T-cell malignancies developing among patients treated with approved BCMA- or CD19 genetically modified autologous CAR T-cell immunotherapies.
On November 28, 2023, the FDA reported on the serious risks of secondary T-cell malignancies developing among patients treated with approved BCMA- or CD19 genetically modified autologous CAR T-cell immunotherapies.
On November 28, 2023, the FDA...
12/05/2023
Oncology
News
Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD
05/03/2024

Amber Denham

Amber Denham
According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...
According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...
According to a recent trial,...
05/03/2024
Oncology
News
FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
05/01/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase...
05/01/2024
Oncology
News
Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the...
04/25/2024
Oncology
News
Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis...
04/25/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
News
Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma
04/23/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG...
04/23/2024
Oncology
News
FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
04/23/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase...
04/23/2024
Oncology
News
FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
04/19/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase...
04/19/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement